Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 ViewZacks Investment Research • 02/04/25
Merck shares plunge on weak 2025 outlook, pause in Gardasil shipments to ChinaProactive Investors • 02/04/25
Merck (MRK) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/04/25
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 OutlookBenzinga • 02/04/25
Merck Canada urges Canadians to take action for their lung health with new “Listen Close” campaignBusiness Wire • 02/04/25
Merck's 2025 revenue outlook falls short as it pauses Gardasil vaccine shipments to ChinaCNBC • 02/04/25
Merck Tops Q4 Forecasts, But Dow Jones Giant Dives On 2025 GuidanceInvestors Business Daily • 02/04/25
The Dow Jones Industrials Are Winning 2025: 4 Highest-Yielding Dogs of the Dow Are Steals24/7 Wall Street • 02/03/25
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab CapvaxiveZacks Investment Research • 02/03/25
Merck Halts Second PAH Drug Study Early on Strong Efficacy ResultsZacks Investment Research • 01/31/25
Unveiling Merck (MRK) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 01/31/25
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in AdultsBusiness Wire • 01/31/25
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final AnalysisBusiness Wire • 01/30/25
Diatech Pharmacogenetics Expands Collaboration with Merck to Enhance Patient Access to Personalized Medicine in the Middle East and AfricaBusiness Wire • 01/29/25